REPL
Replimune Group, Inc.
Price Chart
Latest Quote
$10.19
+0.19 (+1.90%)
Current Price
| Previous Close | $10.00 |
| Open | $10.05 |
| Day High | $10.44 |
| Day Low | $9.90 |
| Volume | 2,571,739 |
Stock Information
| Shares Outstanding | 82.57M |
| Total Debt | $76.35M |
| Cash Equivalents | $269.14M |
| Net Income | $-314.85M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $841.41M |
| EPS (TTM) | $-3.44 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $648.62M |
| Income | $-314.85M |
| Book/sh | $2.64 |
| Cash/sh | $3.26 |
| Employees | 479 |
Financial Ratios
| Quick Ratio | 5.43 |
| Current Ratio | 5.60 |
| Debt/Eq | 36.26 |
Returns & Margins
| ROA | -43.24% |
| ROE | -90.88% |
Ownership
| Insider Ownership | 2.60% |
| Institutional Ownership | 96.95% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.94 |
| P/B | 3.85 |
Analyst Data
| Recommendation | none |
| Target Price | $4.67 |
Technical Indicators
| SMA20 | $8.10 |
| SMA50 | $5.24 |
| SMA200 | $7.05 |
| RSI | 63.20 |
| ATR | 0.9233 |
| Shares Float | 58.34M |
| Short Float | 56.33% |
| Short Ratio | 3.14 |
| Volatility | 0.91 |
| Rel Volume | 0.40 |
Performance History
| Week | +18.21% |
| Month | +116.81% |
| Quarter | +47.90% |
| 6 Months | +6.04% |
| YTD | +14.49% |
| Year | +7.21% |
| 3 Years | -57.72% |
| 5 Years | -70.03% |
| 10 Years | -32.78% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $10.19 | 2,571,300 |
| 2026-06-17 | $10.00 | 4,316,700 |
| 2026-06-16 | $8.78 | 1,550,900 |
| 2026-06-15 | $8.96 | 1,980,800 |
| 2026-06-12 | $8.88 | 1,972,500 |
| 2026-06-11 | $8.62 | 2,052,600 |
| 2026-06-10 | $8.47 | 3,373,800 |
| 2026-06-09 | $9.24 | 2,623,000 |
| 2026-06-08 | $8.97 | 3,142,800 |
| 2026-06-05 | $9.47 | 4,607,800 |
| 2026-06-04 | $9.87 | 7,095,000 |
| 2026-06-03 | $9.98 | 9,007,900 |
| 2026-06-02 | $8.87 | 6,207,400 |
| 2026-06-01 | $9.00 | 10,957,700 |
| 2026-05-29 | $8.69 | 51,373,500 |
| 2026-05-28 | $4.68 | 1,893,100 |
| 2026-05-27 | $4.70 | 2,216,900 |
| 2026-05-26 | $4.60 | 3,600,100 |
| 2026-05-22 | $4.91 | 2,956,500 |
| 2026-05-21 | $5.22 | 4,557,500 |
| 2026-05-20 | $5.16 | 6,041,700 |
| 2026-05-19 | $4.70 | 4,542,300 |
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
đ° Latest News
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
Investor's Business Daily âĸ 2026-06-17T20:15:46Z
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
Zacks âĸ 2026-06-01T17:01:00Z
Why Is REPL Stock Gaining In Pre-Market Today?
Stocktwits âĸ 2026-06-01T10:56:07Z
How Replimuneâs Drug Got Third Chance After White House Intervention
The Wall Street Journal âĸ 2026-05-30T01:53:00Z
Stocks to Watch Recap: Dell, Gap, Costco, SentinelOne
The Wall Street Journal âĸ 2026-05-29T20:53:38Z
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires âĸ 2026-05-29T19:36:59ZREPL Stock Shot Up 80% Today â Whatâs The Deal With FDA?
Stocktwits âĸ 2026-05-29T14:04:35Z
Market Chatter: Replimune Plans to Resubmit Melanoma Therapy Application for FDA Approval
MT Newswires âĸ 2026-05-29T12:21:54ZReplimune Gets Third Try at FDA Approval After Makary Departure
The Wall Street Journal âĸ 2026-05-29T12:19:00Z
Biotech Investors Are Tuning Out the MAHA Chaos
The Wall Street Journal âĸ 2026-05-20T21:26:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $7,893,000 | $6,660,000 | $4,160,000 | $2,223,000 |
| Total Expenses | $259,854,000 | $232,853,000 | $174,166,000 | $115,144,000 |
| Other Income Expense | $20,918,000 | $24,127,000 | $4,330,000 | $-669,000 |
| Other Non Operating Income Expenses | $-202,000 | $771,000 | $-5,676,000 | $-1,059,000 |
| Net Non Operating Interest Income Expense | $-7,893,000 | $-6,660,000 | $-4,160,000 | $-2,223,000 |
| Interest Expense Non Operating | $7,893,000 | $6,660,000 | $4,160,000 | $2,223,000 |
| Operating Expense | $259,854,000 | $232,853,000 | $174,166,000 | $115,144,000 |
| Other Operating Expenses | $-1,773,000 | $-1,920,000 | $-2,914,000 | $-3,170,000 |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-247,297,000 | $-215,794,000 | $-174,284,000 | $-118,036,000 |
| Net Interest Income | $-7,893,000 | $-6,660,000 | $-4,160,000 | $-2,223,000 |
| Normalized Income | $-263,981,800 | $-234,245,240 | $-184,269,988 | $-118,426,000 |
| Net Income From Continuing And Discontinued Operation | $-247,297,000 | $-215,794,000 | $-174,284,000 | $-118,036,000 |
| Total Operating Income As Reported | $-261,627,000 | $-234,773,000 | $-177,080,000 | $-118,314,000 |
| Net Income Common Stockholders | $-247,297,000 | $-215,794,000 | $-174,284,000 | $-118,036,000 |
| Net Income | $-247,297,000 | $-215,794,000 | $-174,284,000 | $-118,036,000 |
| Net Income Including Noncontrolling Interests | $-247,297,000 | $-215,794,000 | $-174,284,000 | $-118,036,000 |
| Net Income Continuous Operations | $-247,297,000 | $-215,794,000 | $-174,284,000 | $-118,036,000 |
| Pretax Income | $-246,829,000 | $-215,386,000 | $-173,996,000 | $-118,036,000 |
| Operating Income | $-259,854,000 | $-232,853,000 | $-174,166,000 | $-115,144,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-3.07 | $-3.24 | $-2.99 | $-2.26 |
| Basic EPS | $-3.07 | $-3.24 | $-2.99 | $-2.26 |
| Other | ||||
| Tax Effect Of Unusual Items | $4,435,200 | $4,904,760 | $20,012 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-256,554,000 | $-229,427,000 | $-177,395,000 | $-114,056,000 |
| Total Unusual Items | $21,120,000 | $23,356,000 | $10,006,000 | $390,000 |
| Total Unusual Items Excluding Goodwill | $21,120,000 | $23,356,000 | $10,006,000 | $390,000 |
| Reconciled Depreciation | $3,502,000 | $2,655,000 | $2,447,000 | $2,147,000 |
| EBITDA (Bullshit earnings) | $-235,434,000 | $-206,071,000 | $-167,389,000 | $-113,666,000 |
| EBIT | $-238,936,000 | $-208,726,000 | $-169,836,000 | $-115,813,000 |
| Diluted Average Shares | $80,564,147 | $66,569,894 | $58,213,010 | $52,212,269 |
| Basic Average Shares | $80,564,147 | $66,569,894 | $58,213,010 | $52,212,269 |
| Diluted NI Availto Com Stockholders | $-247,297,000 | $-215,794,000 | $-174,284,000 | $-118,036,000 |
| Tax Provision | $468,000 | $408,000 | $288,000 | $0 |
| Gain On Sale Of Security | $21,120,000 | $23,356,000 | $10,006,000 | $390,000 |
| Research And Development | $189,447,000 | $174,963,000 | $126,527,000 | $79,545,000 |
| Selling General And Administration | $72,180,000 | $59,810,000 | $50,553,000 | $38,769,000 |
| Other Special Charges | - | - | - | - |
| Other Gand A | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $415,843,000 | $374,508,000 | $555,292,000 | $411,229,000 |
| Total Assets | $551,328,000 | $487,722,000 | $646,591,000 | $461,192,000 |
| Total Non Current Assets | $55,448,000 | $54,055,000 | $53,988,000 | $57,215,000 |
| Other Non Current Assets | $2,903,000 | $1,700,000 | $1,636,000 | $1,636,000 |
| Current Assets | $495,880,000 | $433,667,000 | $592,603,000 | $403,977,000 |
| Other Current Assets | $8,351,000 | $8,077,000 | $6,278,000 | $5,267,000 |
| Receivables | $3,725,000 | $4,922,000 | $2,939,000 | $3,055,000 |
| Other Receivables | $3,725,000 | $4,922,000 | $2,939,000 | $3,055,000 |
| Cash Cash Equivalents And Short Term Investments | $483,804,000 | $420,668,000 | $583,386,000 | $395,655,000 |
| Cash And Cash Equivalents | $111,119,000 | $74,457,000 | $146,590,000 | $105,948,000 |
| Cash Equivalents | $89,900,000 | $41,100,000 | - | - |
| Cash Financial | $21,219,000 | $33,357,000 | - | - |
| Prepaid Assets | - | - | - | $5,267,000 |
| Debt | ||||
| Total Debt | $76,165,000 | $75,869,000 | $60,759,000 | $32,839,000 |
| Long Term Debt And Capital Lease Obligation | $72,182,000 | $71,990,000 | $57,002,000 | $29,207,000 |
| Long Term Debt | $46,377,000 | $44,809,000 | $28,648,000 | - |
| Current Debt And Capital Lease Obligation | $3,983,000 | $3,879,000 | $3,757,000 | $3,632,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $135,485,000 | $113,214,000 | $91,299,000 | $49,963,000 |
| Total Non Current Liabilities Net Minority Interest | $73,123,000 | $72,776,000 | $57,474,000 | $29,207,000 |
| Other Non Current Liabilities | $941,000 | $786,000 | $472,000 | - |
| Current Liabilities | $62,362,000 | $40,438,000 | $33,825,000 | $20,756,000 |
| Other Current Liabilities | $6,069,000 | $3,330,000 | $2,994,000 | $1,320,000 |
| Payables And Accrued Expenses | $32,230,000 | $19,323,000 | $17,165,000 | $10,235,000 |
| Payables | $12,463,000 | $2,578,000 | $5,364,000 | $3,732,000 |
| Accounts Payable | $12,463,000 | $2,578,000 | $5,364,000 | $3,732,000 |
| Equity | ||||
| Common Stock Equity | $415,843,000 | $374,508,000 | $555,292,000 | $411,229,000 |
| Total Equity Gross Minority Interest | $415,843,000 | $374,508,000 | $555,292,000 | $411,229,000 |
| Stockholders Equity | $415,843,000 | $374,508,000 | $555,292,000 | $411,229,000 |
| Gains Losses Not Affecting Retained Earnings | $5,448,000 | $4,855,000 | $5,729,000 | $-973,000 |
| Other Equity Adjustments | $5,448,000 | $4,855,000 | $5,729,000 | $-973,000 |
| Retained Earnings | $-948,579,000 | $-701,282,000 | $-485,488,000 | $-311,204,000 |
| Other | ||||
| Ordinary Shares Number | $77,085,024 | $61,415,105 | $56,676,313 | $47,338,660 |
| Share Issued | $77,085,024 | $61,415,105 | $56,676,313 | $47,338,660 |
| Tangible Book Value | $415,843,000 | $374,508,000 | $555,292,000 | $411,229,000 |
| Invested Capital | $462,220,000 | $419,317,000 | $583,940,000 | $411,229,000 |
| Working Capital | $433,518,000 | $393,229,000 | $558,778,000 | $383,221,000 |
| Capital Lease Obligations | $29,788,000 | $31,060,000 | $32,111,000 | $32,839,000 |
| Total Capitalization | $462,220,000 | $419,317,000 | $583,940,000 | $411,229,000 |
| Additional Paid In Capital | $1,358,897,000 | $1,070,874,000 | $1,034,994,000 | $723,359,000 |
| Capital Stock | $77,000 | $61,000 | $57,000 | $47,000 |
| Common Stock | $77,000 | $61,000 | $57,000 | $47,000 |
| Long Term Capital Lease Obligation | $25,805,000 | $27,181,000 | $28,354,000 | $29,207,000 |
| Current Capital Lease Obligation | $3,983,000 | $3,879,000 | $3,757,000 | $3,632,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $20,080,000 | $13,906,000 | $9,909,000 | $5,569,000 |
| Current Accrued Expenses | $19,767,000 | $16,745,000 | $11,801,000 | $6,503,000 |
| Net PPE | $52,545,000 | $52,355,000 | $52,352,000 | $55,579,000 |
| Accumulated Depreciation | $-13,399,000 | $-9,897,000 | $-7,242,000 | $-4,795,000 |
| Gross PPE | $65,944,000 | $62,252,000 | $59,594,000 | $60,374,000 |
| Leases | $2,504,000 | $1,886,000 | $1,706,000 | $785,000 |
| Construction In Progress | $1,650,000 | $1,117,000 | $783,000 | $1,619,000 |
| Other Properties | $38,806,000 | $41,872,000 | $44,873,000 | $47,646,000 |
| Machinery Furniture Equipment | $22,984,000 | $17,377,000 | $12,232,000 | $10,324,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $372,685,000 | $346,211,000 | $436,796,000 | $289,707,000 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-198,937,000 | $-191,129,000 | $-130,320,000 | $-84,516,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-192,250,000 | $-185,467,000 | $-128,050,000 | $-82,180,000 |
| Cash Flow From Continuing Operating Activities | $-192,250,000 | $-185,467,000 | $-128,050,000 | $-82,180,000 |
| Operating Gains Losses | $-201,000 | $-771,000 | $5,676,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-6,687,000 | $-5,662,000 | $-2,270,000 | $-2,336,000 |
| Investing Cash Flow | $-23,796,000 | $97,201,000 | $-142,502,000 | $-1,806,000 |
| Cash Flow From Continuing Investing Activities | $-23,796,000 | $97,201,000 | $-142,502,000 | $-1,806,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $155,728,000 | $0 | $187,292,000 | $0 |
| Financing Cash Flow | $252,396,000 | $16,283,000 | $311,303,000 | $6,598,000 |
| Cash Flow From Continuing Financing Activities | $252,396,000 | $16,283,000 | $311,303,000 | $6,598,000 |
| Net Common Stock Issuance | $155,728,000 | $0 | $187,292,000 | $0 |
| Common Stock Issuance | $155,728,000 | $0 | $187,292,000 | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-599,000 | $-476,000 | $-365,000 | $-264,000 |
| Issuance Of Debt | $0 | $15,000,000 | $28,154,000 | $0 |
| Interest Paid Supplemental Data | $4,198,000 | $3,044,000 | $1,066,000 | $0 |
| Income Tax Paid Supplemental Data | $105,000 | $300,000 | $0 | $55,000 |
| End Cash Position | $112,822,000 | $76,157,000 | $148,226,000 | $107,584,000 |
| Beginning Cash Position | $76,157,000 | $148,226,000 | $107,584,000 | $184,154,000 |
| Effect Of Exchange Rate Changes | $315,000 | $-86,000 | $-109,000 | $818,000 |
| Changes In Cash | $36,350,000 | $-71,983,000 | $40,751,000 | $-77,388,000 |
| Proceeds From Stock Option Exercised | $97,267,000 | $1,759,000 | $96,222,000 | $6,862,000 |
| Net Issuance Payments Of Debt | $-599,000 | $14,524,000 | $27,789,000 | $-264,000 |
| Net Long Term Debt Issuance | $-599,000 | $14,524,000 | $27,789,000 | $-264,000 |
| Long Term Debt Payments | $-599,000 | $-476,000 | $-365,000 | $-264,000 |
| Long Term Debt Issuance | $0 | $15,000,000 | $28,154,000 | $0 |
| Net Investment Purchase And Sale | $-17,109,000 | $102,863,000 | $-140,232,000 | $530,000 |
| Sale Of Investment | $386,477,000 | $592,379,000 | $443,180,000 | $256,250,000 |
| Purchase Of Investment | $-403,586,000 | $-489,516,000 | $-583,412,000 | $-255,720,000 |
| Net PPE Purchase And Sale | $-6,687,000 | $-5,662,000 | $-2,270,000 | $-2,336,000 |
| Purchase Of PPE | $-6,687,000 | $-5,662,000 | $-2,270,000 | $-2,336,000 |
| Change In Working Capital | $20,970,000 | $2,440,000 | $12,471,000 | $4,708,000 |
| Change In Other Current Liabilities | $-565,000 | $-306,000 | $234,000 | $-73,000 |
| Change In Other Current Assets | $-1,200,000 | $0 | $2,653,000 | $2,527,000 |
| Change In Payables And Accrued Expense | $21,684,000 | $6,440,000 | $13,357,000 | $5,843,000 |
| Change In Accrued Expense | $11,743,000 | $9,234,000 | $11,376,000 | $4,725,000 |
| Change In Payable | $9,941,000 | $-2,794,000 | $1,981,000 | $1,118,000 |
| Change In Account Payable | $9,941,000 | $-2,794,000 | $1,981,000 | $1,118,000 |
| Change In Prepaid Assets | $-252,000 | $-1,778,000 | $-1,059,000 | $-815,000 |
| Change In Receivables | $1,303,000 | $-1,916,000 | $-61,000 | $-247,000 |
| Other Non Cash Items | $4,679,000 | $4,204,000 | $3,147,000 | $2,527,000 |
| Stock Based Compensation | $35,044,000 | $34,125,000 | $28,131,000 | $24,254,000 |
| Amortization Of Securities | $-8,947,000 | $-12,326,000 | $-5,638,000 | $2,220,000 |
| Depreciation Amortization Depletion | $3,502,000 | $2,655,000 | $2,447,000 | $2,147,000 |
| Depreciation And Amortization | $3,502,000 | $2,655,000 | $2,447,000 | $2,147,000 |
| Net Foreign Currency Exchange Gain Loss | $-201,000 | $-771,000 | $5,676,000 | $0 |
| Net Income From Continuing Operations | $-247,297,000 | $-215,794,000 | $-174,284,000 | $-118,036,000 |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-19